**Charity Registration No. 1179130**
**Company Registration No. 07855645 (England and Wales)**
## **GENESIS RESEARCH TRUST**
## **ANNUAL REPORT AND FINANCIAL STATEMENTS**
**FOR THE YEAR ENDED 31 JULY 2023**
## **GENESIS RESEARCH TRUST**
## **LEGAL AND ADMINISTRATIVE INFORMATION**
**Trustees** Professor Lord R M L Winston Professor P R Bennett Professor S Franks Ms A Hodes Mrs L C Loftus Mr A S Rosenfelder **Secretary** Mrs L C Loftus **Charity number** 1179130 **Company number** 07855645 **Director of Services** Stephen Button **Registered office** Wolfson & Weston Research Centre Family Health IRDB Building Imperial College London Hammersmith Hospital Du Cane Road London W12 0NN **Auditor** HW Fisher LLP Acre House 11-15 William Road London NW1 3ER United Kingdom **Bankers** HSBC Bank Plc 281 Chiswick Hgh Road Chiswick London W4 4HJ **Investment advisors** Veritas Investment Management (UK) Limited 90 Long Acre London WC2E 9RA
## **GENESIS RESEARCH TRUST**
## **CONTENTS**
||**Page**|
|---|---|
|Trustees' report|1-7|
|Statement of Trustees' responsibilites|8|
|Independent auditor's report|9 - 11|
|Statement of fnancial actvites|12 - 13|
|Summary income and expenditure account|14|
|Balance sheet|15|
|Statement of cash fows|16|
|Notes to the fnancial statements|17 - 30|
**GENESIS RESEARCH TRUST**
**TRUSTEES’ REPORT (INCLUDING DIRECTORS’ REPORT)**
_**FOR THE YEAR ENDED 31 JULY 2023**_
## **INTRODUCTION**
The Trustees are pleased to present their Trustees’ report together with the financial statements of the charity for the year ended 31 July 2023. The Trustees’ report is also prepared to meet the requirement for a directors’ report for Companies Act purposes.
The financial statements comply with the Companies Act 2006, the Memorandum and Articles of Association, and Accounting and Reporting by Charities: Statements of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).
## **OUR PURPOSE AND ACTIVITIES**
With our building, the Institute of Reproductive and Developmental Biology, celebrating its 25[th] anniversary next year, the Trustees have given a lot of thought to the long-term future of the Genesis Research Trust and its research into the causes and treatment of infertility and the issues concerning parturition and birth. They have agreed to provide further investments over 5 years to establish and maintain three posts for senior scientist and or clinical academics to refresh and maintain the core endeavours of the Genesis Trust. The aim would be to help support these substantive appointments in Imperial College Medical School.
The objectives of the Trust are:
To promote by all available means the study of healthy childbearing, the prevention of diseases peculiar to women; the study of disorders of childbearing and allied subjects and to improve the standard of knowledge of the means of prevention, diagnosis and methods of treatment and cure of such diseases. To initiate, encourage, support, and carry out research and investigation into the causes of such diseases and the possibilities or prevention and alleviation or cure.
To achieve these objectives, the Trust acts as a grant making body, raising funds to provide financial assistance for medical research and for teaching in the field of gynaecology, obstetrics and related fields in paediatrics. Most activities supported by the Trust are centred at the Institute of Reproductive and Developmental Biology at the Wolfson and Weston Research Centre for Family Health and at Queen Charlotte’s and Hammersmith Hospitals. Additionally, the Trust funds some academic activity within the ‘Division of Cancer, Institute of Reproductive Developmental Biology’, Imperial College London.
The Trust is situated in the Institute of Reproductive Developmental Biology (IRDB) Building on the Imperial College Campus at Hammersmith Hospital. This building was opened in February 2002. The bulk of the funds for the building – over £13 million - was raised by The Trust and donated to Imperial College who owns the building now. A Covenant is in place between The Trust and Imperial College that restricts use of the building to activities that are aligned to The Trust’s Objectives.
## **Grant Giving Guidelines**
The Trust operates five funds to support research and educational activities related to women’s health:
- Strategic Development Fund for new initiatives and original research.
- An Equipment Fund for laboratory equipment (for research purposes only).
- A fund specifically for women scientists and clinicians to support a greater number of women within STEM subjects.
- Equipment and Research for teaching purposes.
1
**GENESIS RESEARCH TRUST**
**TRUSTEES’ REPORT (INCLUDING DIRECTORS’ REPORT) (CONTINUED)** _**FOR THE YEAR ENDED 31 JULY 2023**_
- Amenity Funds are generated to support particular research areas of the respective clinicians, academics and scientists. However, these are subject to the Trustees’ discretionary powers.
Applications for grants from the General Research Fund are invited twice a year, up to £50,000 of unrestricted income is available for allocation by the Scientific Advisory Committee at each meeting, totalling c£100,000 of grants from this income per year. Further amounts are awarded by the Board of Trustees each year to relevant research and equipment, with decisions made at the Board meetings.
The Trustees took the decision in the previous year to simplify and focus on a) Grant giving and b) the successful Symposia programmes at Imperial College. It also carried out a reduction in its operating costs to reflect this streamlining in a difficult, lower growth, investment environment while committed to preserving its long-term Endowment Capital.
The net result was a material reduction in new grants for the year. This should however be viewed in the context of a multi-year history of Grants totalling £27 million.
## **Scope of grant making**
To support research into the causes, prevention, diagnosis, and treatment of clinical problems associated with fertility and conception, foetal and maternal diseases and disorders in order to reduce the rates of preterm birth, stillbirth, infertility and diseases of genetic or inherited origin.
## **Eligibility**
Funding is focused on research undertaken within the IRDB at the Hammersmith and Queen Charlotte’s Hospital site though not limited to it. Clinical and scientific staff working on these sites are eligible. The Board of Trustees may occasionally decide to award grants to work undertaken elsewhere including outside Imperial College London, where this fits with a core objective of the Trust.
## **Assessment**
All applications are assessed by the Scientific Advisory Committee. The Scientific Advisory Committee makes recommendations to the Trustees twice a year at Board meetings as to which grants should be awarded. The final decision on successful applications sits with the Board.
## **MEASURES OF SUCCESS**
Our projects are reviewed by our Scientific Advisory Committee and through compulsory external peer review. In addition, each research project is subject to the rigorous academic review processes of Imperial College. Each year the project heads report to the Trust on progress at key intervals and are expected to deliver an annual report of output including publications. Success is judged in terms of impact on our core objectives, new procedures, products and inventions and student progression.
## **Public Benefit**
In shaping our objectives for the year and planning activities, the Trustees have considered the Charity Commission’s guidance on public benefit, including the guidance “public benefit: running a charity (PD2).
Our mission is to reduce harm and suffering to babies and families caused by treatable conditions and complications.
2
**GENESIS RESEARCH TRUST**
## **TRUSTEES’ REPORT (INCLUDING DIRECTORS’ REPORT) (CONTINUED)** _**FOR THE YEAR ENDED 31 JULY 2023**_
We seek to fund research that will deliver the following outcomes in the public benefit:
- Reduction in preterm birth
- Reduction in stillbirth
- Improved treatment for disorders of fertility
- Improved support for families who lose a baby, at every stage in pregnancy
- Improve public understanding of conditions associated with diseases of reproduction
## **ACHIEVEMENTS AND PERFORMANCE**
Overall, the Trust raised £378,883 (2022: £451,412) during the financial year.
## Fundraising Strategy
The Trust fundraises to generate funds for research and grants. Income is generated in the following ways:
- Trust and Foundation funding
- Individual donations
- Corporate sponsorship
- Awards raised by clinicians and scientists from charitable bodies and organisations
- Education and Training events, run by GRT’s Symposium Office
- Income earned on our investments which are carefully managed by professional asset management advisors.
Funds are prudently managed by investing in sterling fixed income assets and listed global equities selected by the Managers
## **Courses and Symposia**
Genesis Research Trust contributes significantly towards postgraduate teaching and medical education through its training programme, run by The Symposium Office. This is a core means of delivering GRT’s purpose as well as to share knowledge and encourage best practice in clinical care.
The target audiences include medical specialists such as GPs, practice nurses, paediatricians, neonatologists, obstetricians, gynaecologists, gynaecological nurses, foetal medicine specialists, radiologists, radiographers, midwives, complementary therapists, physicians, and obstetric anaesthetists.
## **STRUCTURE, GOVERNANCE AND MANAGEMENT**
## **Governing document**
The operating name of the charity is ‘Genesis Research Trust’ (GRT). The charity was first registered as a charity on 7 August 1985. The company was incorporated on 21 November 2011 and is a registered charity constituted as a Limited Company under the Memorandum and Articles of Association. The charity registration number is 1179130 and the company registration number is 07855645.
Genesis Research Trust (the word ‘Limited’ being omitted by licence from the Department of Trade) is registered under the Companies Act 2006 as a company limited by guarantee and not having a capital divided by shares.
3
**GENESIS RESEARCH TRUST**
## **TRUSTEES’ REPORT (INCLUDING DIRECTORS’ REPORT) (CONTINUED)** _**FOR THE YEAR ENDED 31 JULY 2023**_
The core objective of the Trust is the promotion of healthy pregnancy and childbirth. There are no restrictions in the way the charity can operate to meet its objectives. Current funding is directed towards activities undertaken at the Institute of Reproductive Developmental Biology at Imperial College, London and selected other institutions.
## **Recruitment and appointment of Trustees**
As set out in the Articles of Association, the chair of the Board of Trustees is nominated by the Trustees. The Trustees of the organisation are also the directors for the purposes of company law.
The Board of Trustees have power to appoint additional Trustees as it considers fit to do so and there is no limit to the number of years for which a Trustee may serve.
The Trustees who served during the year and up to the date of approval of the financial statements were Professor Lord R M L Winston Professor P R Bennett Professor S Franks Ms A Hodes Mrs L C Loftus Mr A S Rosenfelder
The Trustees have no beneficial interest in the company other than as members and each guarantee to contribute £1 in event of a winding up. Related party transactions are disclosed in note 25.
Trustees have power of discretion over the use of funds held by the Trust but are advised by the Scientific Advisory Committee and the Executive team. Trustees meet annually to set and agree operating strategy, and quarterly to review activities and impact with the executive team.
## **Trustee induction and training**
The Trustees maintain a good working knowledge of charity and company law and best practice. New Trustees are provided with a copy of the company’s Memorandum and Articles of Association and there are informal procedures in place for their training and induction.
## **Organisation**
The Board of Trustees meets regularly during the year to oversee the management of the affairs of the Trust. The Board comprises members from a variety of backgrounds and there are sub-committees dealing with various aspects of the operation. The Director of Services oversees the day-to-day operations of the organisation. All major decisions are ratified by the Board of Trustees.
The Trust is not significantly dependent on the services of unpaid volunteers.
## **Risk review**
The Trustees have established a Finance and Risk Committee to analyse and identify risks facing the Trust and report these risks to the Trustees. The aim is to minimise and reduce risk and the process remains under continuous review.
The Trustees consider the key risks and uncertainties facing the charity and their plans and strategies for managing these risks to be:
4
**GENESIS RESEARCH TRUST**
## **TRUSTEES’ REPORT (INCLUDING DIRECTORS’ REPORT) (CONTINUED)** _**FOR THE YEAR ENDED 31 JULY 2023**_
Long term viability of fundraising: The Trust is diversifying its fundraising strategy to reduce dependence on any one type of activity and increase the scope of its goals.
The Trustees established a Scientific Advisory Committee to fully review each project before granting funds and to provide peer review and check on project outputs to ensure grants are in accordance with the objectives of the Trust.
Website risks in terms of providing reliable information which continues to be under review.
## **Related parties**
The Charity works closely with other similar organisations. None of the charity’s trustees are Directors or Trustees of these other organisations.
## **Pay policy for senior staff**
The finance and remuneration sub-committee reviews annually the salary and employment conditions of the Director of Services, considering performance, market rates and the charity’s financial position.
The Director of Services reviews annually the pay of the team in consultation with the Chair of the Trustees.
## **FINANCIAL REVIEW**
In the year under review, the Trust raised £378,883 (2022: £451,412) and expenditure was £641,063 (2022: £470,067).
## Principal Funding Sources
The principal funding sources are Donations received in the year, amenity funds and symposium income. Details of principal funding sources are shown in notes 3 to 6.
## **Investment powers and policy**
Under the Memorandum and Articles of Association, the charity has the power to make any investment which the Trustees see fit. The Trustees have considered the most appropriate policy for investing funds and have found that cash deposits meet their requirements to generate income.
The managers and trustees were in regular contact throughout the year given the deteriorating outlook to ensure there was sufficient short-term liquidity in the form of cash and short dated bonds to ensure that all commitments could be met. These discussions continued after the year end given the volatility in markets.
## Main Fund.
possible return to a world where a real return could be earned on cash. The por�olio remained cau�ously invested in this uncertain environment and had a bias towards genera�ng income. The return for the 12 months to 31 July 2023 was +0.4% (total return a�er all costs). This modest performance was ahead of the pier group benchmark produced by Asset Risk Consultants of +0.3%. Equi�es as measured by the FT All Share Index (+6.1%) and MSCI AC World (£) +6.8% failed to keep up with infla�on as measured by the UK CPI +6.9%. Rela�vely low risk assets such as Corporate Bonds declined by 4.2% over the same period. Notwithstanding this result, the real value of the por�olio (+21.2% a�er all costs) has been maintained over the last 3 years (UK CPI +20%) and over 5 years the por�olio +39.9%, again a�er all costs, has outperformed UK CPI +3% (+39.7%).
5
**GENESIS RESEARCH TRUST**
## **TRUSTEES’ REPORT (INCLUDING DIRECTORS’ REPORT) (CONTINUED)** _**FOR THE YEAR ENDED 31 JULY 2023**_
## APST Fund.
A similar Investment approach was adopted for this por�olio as for the main fund with the same outcome of +0.4% over the 12 months to 31[st] July 2023. Please see above for various performance comparisons. The fund commenced on the 1[st] February 2021 since when markets have been vola�le. Since incep�on, the total return was 8.8% (a�er all costs) which was ahead of the peer group (+3.2%) as measured by Asset Risk Consultants. Infla�on over this period has been significant (UK CPI +20.1%) but the emphasis in this rela�vely short period has been on capital preserva�on in nominal rather than real returns.
## **Reserves Policy**
The Trust maintains reserves at a level which minimises the impact of short-term income volatility or economic downturn and enables the Trust to manage financial risk. Income is generated through a range of fundraising activities including sponsored challenge and medical conferences. This income is used to fund research that supports the Trust’s core objects. The Trustees are committed to funding vital research that will deliver evidence-based results for reproductive medical treatments and outcomes of worldwide significance. The level of reserves ensures that key research can continue in the event of a temporary shortfall in income.
The Trust’s total reserves at 31 July 2023 were £5,890,977 (2022: £6,229,294). The unrestricted funds not designated or invested in tangible fixed assets held by the charity are £2,893,668 (2022: £3,243,841).
Details of reserves are shown in notes 21-24.
## **FUTURE PLANS AND DEVELOPMENT**
The Trustees reported their intentions last year and Genesis Research Trust has completed the simplification of the non-scientific activities so that the Trust is now in response mode.
In making this change, Trustees are very grateful to all the Team for their continued support and commitment throughout the process. As of the year end, its two principal pillars are Grant making and the series of academic symposia arranged by our Symposium Office team.
The Trustees have also continued to map out the strategy of the Trust to secure the future of our activities at Imperial College. They remain committed to the original objective of undertaking research into women’s health with emphasis on the areas related to pregnancy, reproduction, fertility, epigenetics and some aspects of cancer affecting women. They also recognise that a combination of both academic and translational clinical research will continue to be of importance. The Trust’s historical funding of the Institute of Reproduction and Developmental Biology (IRDB building gifted to Imperial College) resulted in a successful track record. With the allocation of funding from Genesis, the research has helped progress in these areas. The Trustees fully recognise however that more is needed, and this will be supported by the capital available to Genesis which the Trustees plan to supplement over time.
6
**GENESIS RESEARCH TRUST**
## **TRUSTEES’ REPORT (INCLUDING DIRECTORS’ REPORT) (CONTINUED)** _**FOR THE YEAR ENDED 31 JULY 2023**_
The Trustees, while assisting with some limited project funding, will continue to allocate funds over the coming years to support merit-based Ph.D. studentships, each with an expected duration of up to 4 years. The trustees have long recognised they also need to support the creation of academic positions within the IRDB. For some years the search for a suitable clinical academic to fill a chair in reproductive medicine has been unsuccessful. This is partly because movement to London and the high cost of living here has deterred appropriate candidates. We recognise that clinical academic leaders will be essential for the continued success of work in the IRDB, and the trustees have considered supporting promising younger candidates to grow into maintaining the life and excellence of the intellectual and scientific capital the trust wishes to promote. The Trustees anticipate funding such posts internally and in collaboration with partners.
## **Going concern**
The Trustees completed a review of the Trust’s planned symposium and other programs, processes have been put in place to ensure the viability of the Trust and its commitment to meeting its primary objective of research funding. The Trust, through its existing reserves is well positioned to meet all its commitments in grants and scholarships. The Trustees have a reasonable expectation that the Trust has adequate resources to continue in operational existence for the foreseeable future. Thus the Trustees continue to adopt the going concern basis of accounting in preparing the financial statements.
## **Statement of Fundraising Practice**
The Trustees wish to acknowledge and thank our dedicated fundraisers who have undertaken a challenge event over the past year in support of Genesis Research Trust. We also appreciate the Trusts and companies who have supported the charity.
We seek to adhere to the highest standards of fundraising practice. Our fundraising activities comply with the standards in the Code of Fundraising Practice.
We have received no complaints about our fundraising this year. We also pay close attention to the changing regulatory environment to ensure that we remain compliant with best practice and that any fundraising is transparent, honest, and non-intrusive. We did not employ professional fundraising agencies.
## **Disclosure of information to auditor**
Each of the Trustees has confirmed that there is no information of which they are aware which is relevant to the audit, but of which the auditor is unaware. They have further confirmed that they have taken appropriate steps to identify such relevant information and to establish that the auditor is aware of such information.
## **Auditor**
HW Fisher LLP was appointed auditor to the charity and a resolution proposing that the firm be re-appointed will be put to the next Annual General Meeting.
## **On behalf of the Board of Trustees**
Robert ML Winston
------------------------------------------------Professor Lord R M L Winston **Trustee**
Date: 12 Apr 2024
7
## **GENESIS RESEARCH TRUST**
## **STATEMENT OF TRUSTEES' RESPONSIBILITIES**
## _**FOR THE YEAR ENDED 31 JULY 2023**_
The Trustees, who are also the directors of Genesis Research Trust for the purpose of company law, are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).
Company Law requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the Trust and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that year.
In preparing these financial statements, the Trustees are required to:
- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Trust will continue in operation.
The Trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the Trust and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Trust and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.
- 8 -
## **GENESIS RESEARCH TRUST**
## **INDEPENDENT AUDITOR'S REPORT**
## **TO THE MEMBERS OF GENESIS RESEARCH TRUST**
## **Opinion**
We have audited the financial statements of Genesis Research Trust (the ‘Trust’) for the year ended 31 July 2023 which comprise the statement of financial activities, the summary income and expenditure account, the balance sheet, the statement of cash flows and the notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including FRS 102 _The Financial Reporting Standard applicable in the UK and Republic of Ireland_ (United Kingdom Generally Accepted Accounting Practice).
In our opinion, the financial statements:
- give a true and fair view of the state of the charitable company's affairs as at 31 July 2023 and of its incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.
## **Basis for opinion**
We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the _Auditor's responsibilities for the audit of the financial statements_ section of our report. We are independent of the Trust in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.
## **Conclusions relating to going concern**
In auditing the financial statements, we have concluded that the Trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.
Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Trust’s ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.
Our responsibilities and the responsibilities of the Trustees with respect to going concern are described in the relevant sections of this report.
## **Other information**
The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The Trustees are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.
We have nothing to report in this regard.
**Opinions on other matters prescribed by the Companies Act 2006**
In our opinion, based on the work undertaken in the course of our audit:
- the information given in the Trustees' report, which includes the directors' report prepared for the purposes of company law, for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the directors' report included within the Trustees' report has been prepared in accordance with applicable legal requirements.
## **Matters on which we are required to report by exception**
In the light of the knowledge and understanding of the Trust and its environment obtained in the course of the audit, we have not identified material misstatements in the directors' report included within the Trustees' report.
- 9 -
## **GENESIS RESEARCH TRUST**
## **INDEPENDENT AUDITOR'S REPORT (CONTINUED)**
## **TO THE MEMBERS OF GENESIS RESEARCH TRUST**
We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:
- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit; or
- the Trustees were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies' exemptions in preparing the Trustees' report and from the requirement to prepare a strategic report.
## **Responsibilities of Trustees**
As explained more fully in the statement of Trustees' responsibilities, the Trustees, who are also the directors of the Trust for the purpose of company law, are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the Trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the financial statements, the Trustees are responsible for assessing the Trust’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.
## **Auditor's responsibilities for the audit of the financial statements**
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.
Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.
As part of our planning process:
- We enquired of management the systems and controls the charity has in place, the areas of the financial statements that are most susceptible to the risk of irregularities and fraud, and whether there was any known, suspected or alleged fraud. The charity did not inform us of any known, suspected or alleged fraud.
- We obtained an understanding of the legal and regulatory frameworks applicable to the charity. We determined that the following were most relevant: the Charity SORP, FRS 102, Charities Act 2011 and Companies Act 2006.
- We considered the incentives and opportunities that exist in the charity, including the extent of management bias, which present a potential for irregularities and fraud to be perpetuated, and tailored our risk assessment accordingly.
- Using our knowledge of the charity, together with the discussions held with the charity at the planning stage, we formed a conclusion on the risk of misstatement due to irregularities including fraud and tailored our procedures according to this risk assessment.
- The key procedures we undertook to detect irregularities including fraud during the course of the audit included:
- Identifying and testing journal entries and the overall accounting records, in particular those that were significant and unusual.
- Reviewing the financial statement disclosures and determining whether accounting policies have been appropriately applied.
- Verifying of bank and investments balances to third party confirmations.
- Testing key income lines for evidence of management bias.
- Assessing the extent of compliance, or lack of, with the relevant laws and regulations.
- Assessing the validity of the classification of income, expenditure, assets and liabilities between unrestricted, restricted and endowment funds.
- Documenting and verifying all significant related party balances and transactions.
- Reviewing documentation such as the charity board minutes, for discussions of irregularities including fraud.
- 10 -
## **GENESIS RESEARCH TRUST**
## **INDEPENDENT AUDITOR'S REPORT (CONTINUED) TO THE MEMBERS OF GENESIS RESEARCH TRUST**
Owing to the inherent limitations of an audit, there is an unavoidable risk that we may not have detected some material misstatements in the financial statements even though we have properly planned and performed our audit in accordance with auditing standards. The primary responsibility for the prevention and detection of irregularities and fraud rests with the trustees of the charity.
A further description of our responsibilities is available on the Financial Reporting Council’s website at: https://www.frc.org.uk/ auditorsresponsibilities. This description forms part of our auditor's report.
## **Use of our report**
This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charitable company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company’s members as a body, for our audit work, for this report, or for the opinions we have formed.
## Andrew Rich
## **Andrew Rich (Senior Statutory Auditor)**
## **for and on behalf of HW Fisher LLP**
Chartered Accountants Statutory Auditor Acre House 11-15 William Road London NW1 3ER United Kingdom
......................... 12 Apr 2024
- 11 -
## **GENESIS RESEARCH TRUST**
## **STATEMENT OF FINANCIAL ACTIVITIES**
## _**FOR THE YEAR ENDED 31 JULY 2023**_
|**Current fnancial year**
**Unrestricted**
**Unrestricted**
**funds**
**funds**
**general**
**designated**
**2023**
**2023**
**Notes**
**£**
**£**
**Income from:**
Donatons and legacies
**3**
38,755
54,552
Charitable actvites
**4**
139,804
-
Fundraising actvites
**5**
4,155
-
Investments
**6**
87,654
-
**Total income**
270,368
54,552
**Expenditure on:**
Raising funds
**7**
34,055
-
Charitable actvites
**8**
541,808
49,131
**Total resources expended**
575,863
49,131
Net (losses)/gains on
investments
**13**
(44,678)
-
**Net movement in funds**
(350,173)
5,421
Fund balances at 1 August
2022
3,243,841
613,197
**Fund balances at 31 July**
**2023**
2,893,668
618,618|**Restricted**
**Endowment**
**funds**
**funds**
**2023**
**2023**
**£**
**£**
-
-
-
-
-
-
53,963
-
53,963
-
-
16,069
-
-
-
16,069
-
(31,459)
53,963
(47,528)
113,862
2,258,394
167,825
2,210,866|**Total**
**2023**
**£**
93,307
139,804
4,155
141,617
378,883
50,124
590,939
641,063
(76,137)
(338,317)
6,229,294
5,890,977|Total
2022
**£**
127,117
232,710
1,000
90,585|
|---|---|---|---|
||||451,412|
||||49,269|
||||420,798|
||||470,067|
||||154,890|
||||136,235
6,093,059|
||||6,229,294|
The statement of financial activities includes all gains and losses recognised in the year.
All income and expenditure derive from continuing activities.
- 12 -
## **GENESIS RESEARCH TRUST**
## **STATEMENT OF FINANCIAL ACTIVITIES (CONTINUED)** _**FOR THE YEAR ENDED 31 JULY 2023**_
|**Prior fnancial year**
**Unrestricted**
**Unrestricted**
**funds**
**funds**
**general**
**designated**
**2022**
**2022**
**Notes**
**£**
**£**
**Income from:**
Donatons and legacies
**3**
96,880
30,237
Charitable actvites
**4**
232,710
-
Fundraising actvites
**5**
1,000
-
Investments
**6**
58,729
-
**Total income**
389,319
30,237
**Expenditure on:**
Raising funds
**7**
32,942
-
Charitable actvites
**8**
350,434
54,796
**Total resources expended**
383,376
54,796
Net gains/(losses) on investments
**13**
100,453
-
**Net (outgoing)/incoming resources**
**before transfers**
106,396
(24,559)
Gross transfers between funds
(36,993)
36,993
**Net movement in funds**
69,403
12,434
Fund balances at 1 August 2021
3,174,438
600,763
**Fund balances at 31 July 2022**
3,243,841
613,197|**Restricted**
**Endowment**
**funds**
**funds**
**2022**
**2022**
**£**
**£**
-
-
-
-
-
-
31,856
-
31,856
-
-
16,327
15,568
-
15,568
16,327
-
54,437
16,288
38,110
-
-
16,288
38,110
97,574
2,220,284
113,862
2,258,394|**Total**
**2022**
**£**
127,117
232,710
1,000
90,585|
|---|---|---|
|||451,412|
|||49,269|
|||420,798|
|||470,067|
|||154,890|
|||136,235
-|
|||136,235
6,093,059|
|||6,229,294|
The statement of financial activities includes all gains and losses recognised in the year.
All income and expenditure derive from continuing activities.
- 13 -
## **GENESIS RESEARCH TRUST**
## **SUMMARY INCOME AND EXPENDITURE ACCOUNT**
## _**FOR THE YEAR ENDED 31 JULY 2023**_
|**All income funds**
**2023**
**£**
Gross income
**378,883**
(Losses)/gains on investments
**(44,678)**
Total income in the reportng period
**334,205**
Total expenditure from income funds
**624,994**
**Net (expenditure)/income for the year**
**(290,789)**|2022
£
451,412
100,453|
|---|---|
||551,865
453,740|
||98,125|
- 14 -
## **GENESIS RESEARCH TRUST**
## **BALANCE SHEET**
## _**AS AT 31 JULY 2023**_
|**2023**
**Notes**
**£**
**Fixed assets**
Investments
**15**
**Current assets**
Debtors
**17**
7,944
Cash at bank and in hand
177,158
185,102
**Creditors: amounts falling due within one year**
**18**
(382,538)
Net current liabilites
**Total assets less current liabilites**
**Creditors: amounts falling due afer more than**
**one year**
**19**
**Net assets**
**Capital funds**
Endowment funds
**21**
**Income funds**
Restricted funds
**22**
Unrestricted funds
Designated funds
**23**
618,618
General unrestricted funds
2,893,668
The fnancial statements were approved by the Trustees on .........................
12 Apr 2024|**£**
6,267,894
(197,436)
6,070,458
(179,481)
5,890,977
2,210,866
167,825
3,512,286
5,890,977|**2022**
**£**
2,322
59,910
62,232
(348,057)
613,197
3,243,841|**£**
6,515,119
(285,825)
6,229,294
-
6,229,294
2,258,394
113,862
3,857,038
6,229,294|
|---|---|---|---|
## Robert ML Winston
..............................
Professor Lord R M L Winston
**Trustee**
**Company Registration No. 07855645**
- 15 -
## **GENESIS RESEARCH TRUST**
## **STATEMENT OF CASH FLOWS**
## _**FOR THE YEAR ENDED 31 JULY 2023**_
|**Notes**
**Cash fows from operatng actvites**
Cash absorbed by operatons
**26**
**Investng actvites**
Cash (invested in)/withdrawn from investment
portolio
**Net cash generated from investng actvites**
**Net cash used in fnancing actvites**
**Net increase/(decrease) in cash and cash equivalents**
Cash and cash equivalents at beginning of year
**Cash and cash equivalents at end of year**|**2023**
**£**
**£**
(150,031)
267,279
267,279
-
117,248
59,910
177,158|**2022**
**£**
**£**
(119,211)
107,239
107,239
-
(11,972)
71,882
59,910|
|---|---|---|
- 16 -
## **GENESIS RESEARCH TRUST**
## **NOTES TO THE FINANCIAL STATEMENTS**
## _**FOR THE YEAR ENDED 31 JULY 2023**_
## **1 Accounting policies**
## **Charity information**
Genesis Research Trust is a private company limited by guarantee governed by its Memorandum and Articles of Association and incorporated in England and Wales. The registered office is Wolfson & Weston Research Centre Family Health, IRDB Building, Imperial College London, Hammersmith Hospital, Du Cane Road, London, W12 0NN.
## **1.1 Accounting convention**
The financial statements have been prepared in accordance with the Trust's governing document, the Companies Act 2006 and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)". The Trust is a Public Benefit Entity as defined by FRS 102.
The financial statements are prepared in sterling, which is the functional currency of the Trust. Monetary amounts in these financial statements are rounded to the nearest £.
The financial statements have been prepared under the historical cost convention, modified to include the valuation of certain financial instruments at fair value. The principal accounting policies adopted are set out below.
## **1.2 Going concern**
The Trustees completed a review of the Trust’s planned symposium and other programs, processes have been put in place to ensure the viability of the Trust and its commitment to meeting its primary objective of research funding.
The Trust, through its existing reserves is well positioned to meet all of its commitments in grants and scholarships.
The Trustees have a reasonable expectation that the Trust has adequate resources to continue in operational existence for the foreseeable future. Thus the Trustees continue to adopt the going concern basis of accounting in preparing the financial statements
## **1.3 Charitable funds**
Unrestricted funds are available for use at the discretion of the Trustees in furtherance of their charitable objectives.
Designated funds comprise funds which have been set aside at the discretion of the Trustees for specific purposes. The purposes and uses of the designated funds are set out in the notes to the financial statements.
Restricted funds are subject to specific conditions by donors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.
Endowment funds are subject to specific conditions by donors that the capital must be maintained by the Trust.
## **1.4 Income**
Income is recognised when the Trust is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.
Cash donations are recognised on receipt. Other donations are recognised once the Trust has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation. Services in kind are recognised at the value the Trust would be prepared to pay on the open market for what it receives.
Legacies are recognised on receipt or otherwise if the Trust has been notified of an impending distribution, the amount is known, and receipt is expected. If the amount is not known, the legacy is treated as a contingent asset.
Gifts in kind comprise the provision of office space. Gifts in kind are included in income and expenditure at a reasonable estimate of their value to the charity.
- 17 -
## **GENESIS RESEARCH TRUST**
## **NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**
## _**FOR THE YEAR ENDED 31 JULY 2023**_
- **1 Accounting policies**
**(Continued)**
Government grants are recognised at the fair value of the amount received or receivable when thereis reasonable assurance that the grant conditions will be met and the grants will be received. The charity received grants under the Coronavirus Job Retention Scheme. The scheme is designed to compensate for staff costs, so amounts received or receivable are recognised in the income statement as part of other operating income over the same period as the costs to which they relate. Government grants are accounted for under the performance model.
## **1.5 Expenditure**
Expenditure is recognised on an accruals basis, inclusive of value added tax.
Expenditure relating to charitable activities are those elements of expenditure directly incurred in performing these activities.
Grants payable are payments made to third parties in the furtherance of the charitable objects of the charity. In the case of an unconditional grant offer this is accrued once the recipient has been notified of the grant award.
Support costs are allocated based on the proportion of direct costs allocated to each activity.
Governance costs comprise all costs involving the public accountability of the charity and its compliance with regulation and good practice.
## **1.6 Tangible fixed assets**
Tangible fixed assets are initially measured at cost and subsequently measured at cost, net of depreciation and any impairment losses.
Depreciation is recognised so as to write off the cost of assets less their residual values over their useful lives on the following bases:
Computers 3 years straight line
The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in net income/(expenditure) for the year.
## **1.7 Fixed asset investments**
Fixed asset investments are initially measured at transaction price excluding transaction costs, and are subsequently measured at fair value at each reporting date. Changes in fair value are recognised in net income/(expenditure) for the year. Transaction costs are expensed as incurred.
## **1.8 Cash and cash equivalents**
Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less.
- 18 -
## **GENESIS RESEARCH TRUST**
## **NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)** _**FOR THE YEAR ENDED 31 JULY 2023**_
## **1 Accounting policies**
**(Continued)**
## **1.9 Financial instruments**
The Trust has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.
The charity and group only have financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value except for those financial assets classified as at fair value through profit or loss, which are initially measured at fair value (which is normally the transaction price excluding transaction costs).
Financial instruments are recognised in the Trust's balance sheet when the Trust becomes party to the contractual provisions of the instrument.
Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.
## **1.10 Employee benefits**
The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.
Termination benefits are recognised immediately as an expense when the Trust is demonstrably committed to terminate the employment of an employee or to provide termination benefits.
## **1.11 Retirement benefits**
Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.
## **2 Critical accounting estimates and judgements**
In the application of the Trust’s accounting policies, the Trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.
The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods. There were no significant accounting estimates or judgements in the year.
## **3 Donations and legacies**
|**Unrestricted**
**Unrestricted**
**funds**
**funds**
**general**
**designated**
**2023**
**2023**
**£**
**£**
Donatons and gifs
38,755
54,552
Grants received
-
-
38,755
54,552|**Total**
Unrestricted
Unrestricted
funds
funds
general
designated
**2023**
2022
2022
**£**
£
£
93,307
87,730
30,237
-
9,150
-
93,307
96,880
30,237|Total
2022
£
117,967
9,150|
|---|---|---|
|||127,117|
- 19 -
## **GENESIS RESEARCH TRUST**
## **NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)** _**FOR THE YEAR ENDED 31 JULY 2023**_
- **3 Donations and legacies**
|**Donatons and legacies**
**Donatons and gifs**
Donatons
Services in kind (ofce space)
**Grants receivable for core actvites**
Government grant - CJRS|1,705
37,050
38,755
-
-|54,552
-
54,552
-
-|56,257
37,050
93,307
-
-|50,680
37,050
87,730
9,150
9,150|**(Contnued)**
30,237
80,917
-
37,050
30,237
117,967
-
9,150
-
9,150|**(Contnued)**
30,237
80,917
-
37,050
30,237
117,967
-
9,150
-
9,150|
|---|---|---|---|---|---|---|
|||||||117,967|
|||||||9,150|
|||||||9,150|
## **4 Charitable activities**
|**Unrestricted**
**funds**
**Unrestricted**
**funds**
**2023**
**2022**
**£**
**£**
Symposium Programme
139,804
232,710|**Unrestricted**
**funds**
**Unrestricted**
**funds**
**2023**
**2022**
**£**
**£**
Symposium Programme
139,804
232,710|**Unrestricted**
**funds**
**Unrestricted**
**funds**
**2023**
**2022**
**£**
**£**
Symposium Programme
139,804
232,710|
|---|---|---|
||**2023**
**£**
139,804|**2022**
**£**
232,710|
||||
|**Fundraising actvites**|||
|**Unrestricted**
Unrestricted
**funds**
funds
**general**
general
**2023**
2022
**£**
£
Fundraising events
4,155
1,000
**Investments**
**Unrestricted**
**Restricted**
**Total**
Unrestricted
Restricted
Total
**funds**
**funds**
funds
funds
**general**
general
**2023**
**2023**
**2023**
2022
2022
2022
**£**
**£**
**£**
£
£
£
Income from listed
investments
87,654
53,963
141,617
58,729
31,856
90,585|||
|||Total
2022
£
90,585|
## **5 Fundraising activities**
## **6 Investments**
- 20 -
## **GENESIS RESEARCH TRUST**
## **NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)** _**FOR THE YEAR ENDED 31 JULY 2023**_
## **7 Raising funds**
|**Unrestricted**
**Endowment**
**funds**
**funds**
**general**
**2023**
**2023**
**£**
**£**
Fundraising and publicity
Consultancy and other
fundraising costs
2,773
-
Fundraising event costs
1,925
-
Staf costs
-
-
Fundraising and publicity
4,698
-
Investment management
29,357
16,069
34,055
16,069|**Total**
Unrestricted
Endowment
funds
funds
general
**2023**
2022
2022
**£**
£
£
2,773
1,476
-
1,925
-
-
-
1,167
-
4,698
2,643
-
45,426
30,299
16,327
50,124
32,942
16,327|Total
2022
£
1,476
-
1,167|
|---|---|---|
|||2,643|
|||46,626|
|||49,269|
- 21 -
## **GENESIS RESEARCH TRUST**
## **NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**
## _**FOR THE YEAR ENDED 31 JULY 2023**_
## **8 Charitable activities**
|**Symposium**
**Programme**
**Medical**
**Research**
**Programme**
**2023**
**2023**
**£**
**£**
Staf costs
45,585
-
Conferences, travel,
accommodaton & lecture fees
56,557
-
Other costs
-
49,131
102,142
49,131
Grant funding of actvites (see
note 9)
-
278,260
Share of support costs (see
note 10)
139,699
-
Share of governance costs (see
note 10)
-
21,707
241,841
349,098
**Analysis by fund**
Unrestricted funds - general
241,841
299,967
Designated funds
-
49,131
Restricted funds
-
-
241,841
349,098|**Total**
**2023**
**Symposium**
**Programme**
**Medical**
**Research**
**Programme**
**2022**
**2022**
**£**
**£**
**£**
45,585
53,632
-
56,557
114,991
-
49,131
-
82,378
151,273
168,623
82,378
278,260
-
-
139,699
149,287
-
21,707
-
20,510
590,939
317,910
102,888
541,808
317,910
32,524
49,131
-
54,796
-
-
15,568
590,939
317,910
102,888|**Total**
**2022**
**£**
53,632
114,991
82,378|
|---|---|---|
|||251,001
-
149,287
20,510|
|||420,798|
|||350,434
54,796
15,568|
|||420,798|
## **9 Grants payable**
Grants to institutions: Imperial College
|**Medical**|
Medical|
|---|---|
|**Research**|Research|
|**Programme**|Programme|
|**2023**|2022|
|**£**|£|
|278,260|-|
- 22 -
## **GENESIS RESEARCH TRUST**
## **NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)** _**FOR THE YEAR ENDED 31 JULY 2023**_
|**10**
**Support costs**
**Support costs**
**Governance**
**costs**
**£**
**£**
Staf costs
60,216
-
Depreciaton
-
-
Premises & equipment costs
45,995
-
Legal & professional costs
25,394
-
Other costs
8,094
-
Audit fees
-
16,707
Accountancy
-
5,000
139,699
21,707
Analysed between
Charitable actvites
139,699
21,707|**2023**
Support costs
Governance
costs
**£**
£
£
60,216
77,915
-
-
493
-
45,995
43,535
-
25,394
23,756
-
8,094
3,588
-
16,707
-
15,510
5,000
-
5,000
161,406
149,287
20,510
161,406
149,287
20,510|2022
£
77,915
493
43,535
23,756
3,588
15,510
5,000|
|---|---|---|
|||169,797|
|||169,797|
Governance costs includes payments to the auditors of £16,707 (2022: £15,510) for audit fees and £5,000 (2022: £5,000) for statutory accounts assistance and general advice.
## **11 Trustees**
None of the Trustees (or any persons connected with them) received any remuneration or benefits from the Trust during the year.
Key management personnel comprises the Trustees and Chief Executive. The total employee benefits of the eey management personnel of the charity were £42,024 (2022: £46,812) which related to the Chief Executive.
- 23 -
## **GENESIS RESEARCH TRUST**
## **NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)** _**FOR THE YEAR ENDED 31 JULY 2023**_
## **12 Employees**
The average monthly number of employees during the year was:
|Direct charitable wore
Administratve wore
Total
**Employment costs**
Wages and salaries
Social security costs
Other pension costs|**2023**
**Number**
2
2
4
**2023**
**£**
98,574
5,864
1,363
105,801|**2022**
**Number**
2
3|
|---|---|---|
|||5|
|||**2022**
**£**
121,760
9,115
1,839|
|||132,714|
Wages and salaries include termination payments totalling £nil (2022: £nil).
There were no employees whose annual remuneration was £60,000 or more.
## **13 Net gains/(losses) on investments**
|**Unrestricted**
**Endowment**
**funds**
**funds**
**general**
**2023**
**2023**
**£**
**£**
Revaluaton of investments
(28,526)
(14,228)
Gain/(loss) on sale of
investments
(16,152)
(17,231)
(44,678)
(31,459)|**Total**
Unrestricted
Endowment
funds
funds
general
**2023**
2022
2022
**£**
£
£
(42,754)
94,884
65,089
(33,383)
5,569
(10,652)
(76,137)
100,453
54,437|Total
2022
£
159,973
(5,083)|
|---|---|---|
|||154,890|
- 24 -
## **GENESIS RESEARCH TRUST**
## **NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**
## _**FOR THE YEAR ENDED 31 JULY 2023**_
## **14 Tangible fixed assets**
|**Cost**
At 1 August 2022
At 31 July 2023
**Depreciaton and impairment**
At 1 August 2022
At 31 July 2023
**Carrying amount**
At 31 July 2023
At 31 July 2022|**Computers**
**£**
4,414|
|---|---|
||4,414|
||4,414|
||4,414|
||-|
||-|
## **15 Fixed asset investments**
|**Cost or valuaton**
At 1 August 2022
Additons
Valuaton changes
Cash withdrawn
Investment income
Investment management fees
Disposals
At 31 July 2023
**Carrying amount**
At 31 July 2023
At 31 July 2022|**Listed**
**Commodites Cash in portolio**
**£**
**£**
**£**
4,896,687
104,951
1,513,481
1,771,405
-
(1,771,405)
(48,460)
5,706
-
-
-
(267,279)
-
-
141,617
-
-
(45,426)
(907,994)
-
874,611
5,711,638
110,657
445,599
5,711,638
110,657
445,599
4,896,687
104,951
1,513,481|**Total**
**£**
6,515,119
-
(42,754)
(267,279)
141,617
(45,426)
(33,383)|
|---|---|---|
||**£**
4,896,687
1,771,405
(48,460)
-
-
-
(907,994)
5,711,638
5,711,638
4,896,687||
|||6,267,894|
|||6,267,894|
|||6,515,119|
**16 Financial instruments**
|**Financial instruments**
**Carrying amount of fnancial assets**
Instruments measured at fair value through proft or loss|**2023**
**£**
5,711,638|**2022**
**£**
4,896,687|
|---|---|---|
||||
|Fair value is determined by a quoted mareet price in an actve mareet.|||
- 25 -
## **GENESIS RESEARCH TRUST**
## **NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**
## _**FOR THE YEAR ENDED 31 JULY 2023**_
|**17**
**Debtors**
**Amounts falling due within one year:**
Prepayments and accrued income
**18**
**Creditors: amounts falling due within one year**
Trade creditors
Grants due within one year
Accruals
**19**
**Creditors: amounts falling due afer more than one year**
Grants due afer one year|(Continued)
**2023**
**2022**
**£**
**£**
7,944
2,322
**2023**
**2022**
**£**
**£**
66,570
72,504
272,882
248,179
43,086
27,374
382,538
348,057
**2023**
**2022**
**£**
**£**
179,481
-|(Continued)
**2023**
**2022**
**£**
**£**
7,944
2,322
**2023**
**2022**
**£**
**£**
66,570
72,504
272,882
248,179
43,086
27,374
382,538
348,057
**2023**
**2022**
**£**
**£**
179,481
-|
|---|---|---|
|||**2022**
**£**
72,504
248,179
27,374|
|||348,057|
|||**2022**
**£**
-|
## **20 Retirement benefit schemes**
## **Defined contribution schemes**
The Trust operates a defined contribution pension scheme for all qualifying employees. The assets of the scheme are held separately from those of the Trust in an independently administered fund.
The charge to profit or loss in respect of defined contribution schemes was £1,363 (2022 - £1,839).
- 26 -
##
|**Endowment funds**|Endowment funds represent assets which must be held permanently by the Trust. Income arising on the endowment funds can be used in accordance with the objects of the Trust and is included|as restricted income. Any capital gains or losses arising on the assets form part of the fund.|**Movement in funds**
**Movement in funds**|**Balance at**
**Incoming**
**Resources**
**Transfers**
**Revaluatons**
**Balance at**
**Incoming**
**Resources**
**Transfers**
**Revaluatons**
**Balance at**|**1 August 2021**
**resources**
**expended**
**gains and losses**
**1 August 2022**
**resources**
**expended**
**gains and losses**
**31 July 2023**|**£**
**£**
**£**
**£**
**£**
**£**
**£**
**£**
**£**
**£**
**£**|**Permanent endowments**|Angela Patman|scholarships fund
2,220,284
-
(16,327)
-
54,437
2,258,394
-
(16,069)
-
(31,459)
2,210,866|2,220,284
-
(16,327)
-
54,437
2,258,394
-
(16,069)
-
(31,459)
2,210,866||The Angela Patman scholarships fund: A permanent endowment gif (Angela Patman Scholarship Trust - APST) of £2,045,159 (net of expenses) was received by the Trust in 2020. A further sum|received in 2021 represented the adjustment for the fnal selling prices of the propertes lef under the Will. The Trust will follow the wishes of the late Setlor which were as follows:|"To promote the further educaton of students of limited fnancial means studying at The Imperial College School of Medicine (the “College”) (or any successor insttuton should the College|merge with another insttuton or otherwise cease to exist) by the award which shall be at their discreton of one bursary per annum in full or part consideraton of the fees required for the study|of medicine at the College together or to cover or partly cover the living and other expenses of such students."|Income generated by the investments is credited to a specifc restricted fund.|The Trustees have decided to apply a total return on investment approach in respect of establishing the amount of funds available.|The trusteeship of the APST was transferred to the Trust by a Charity Commission Scheme dated 24 March 2020. The Commission also issued a directon to link the APST with the Trust for|accountng and charity registraton purposes. The Trust is the sole trustee of the APST and can account for APST within GRT’s accounts however, the APST remains a separate linked charity|( Charity number: 1179130-1).|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|**21**||||||||||||||||||||||
## **GENESIS RESEARCH TRUST**
## **NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)** _**FOR THE YEAR ENDED 31 JULY 2023**_
## **22 Restricted funds**
The income funds of the charity include restricted funds comprising the following unexpended balances of donations and grants held on trust for specific purposes:
|||**Movement in funds**|**Movement in funds**||**Movement in**||
|---|---|---|---|---|---|---|
||||||**funds**||
||**Balance at**|**Incoming**|**Resources**|**Balance at**|**Incoming**|**Balance at**|
||**1 August 2021**|**resources**|**expended**|**1 August 2022**|**resources**|**31 July 2023**|
||**£**|**£**|**£**|**£**|**£**|**£**|
|Angela Patman Scholarships|6,803|31,856|(15,568)|23,091|53,963|77,054|
|Pre-term Labour Research|61,676|-|-|61,676|-|61,676|
|Prostrate Cancer Research|26,090|-|-|26,090|-|26,090|
|Ultrasound|3,005|-|-|3,005|-|3,005|
||97,574|31,856|(15,568)|113,862|53,963|167,825|
The restricted funds represent amounts received by the charity for specific purposes as shown below:
**Angela Pattman Scholarships:** Income generated by the endowment fund as detailed in note 21.
**Pre-term Labour Research Fund** : represents specific research funds received from Observa Pharmaceutical Company.
**Prostate Cancer Research Fund** : represents funds provided for the specific work carried out by Professor I Huhtaniemi into the research of prostate cancer.
**Ultrasound Fund** : The award was made in 2017 to buy an ultrasound equipment. There has been no movement since 2017.
- 28 -
##
##
||||**Balance at**|**31 July 2023**|**£**|546,996|71,622|618,618|||||Total||2022|£|||6,515,119|(285,825)|-|6,229,294|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|**Designated funds**|The income funds of the charity include the following designated funds which have been set aside out of unrestricted funds by the trustees for specifc purposes:|**Movement in funds**
**Movement in funds**|**Balance at**
**Incoming**
**Resources**
**Transfers**
**Balance at**
**Incoming**
**Resources**|**1 August 2021**
**resources**
**expended**
**1 August 2022**
**resources**
**expended**|**£**
**£**
**£**
**£**
**£**
**£**
**£**|Miscellaneous Amenity Funds
529,141
30,237
(54,796)
36,993
541,575
54,552
(49,131)|Miscellaneous Research Grants
71,622
-
-
-
71,622
-
-|600,763
30,237
(54,796)
36,993
613,197
54,552
(49,131)||**Miscellaneous Amenity Funds**: represent funds set aside for Research grants, symposium and travel cost to the symposiums|**Miscellaneous Research Grants**: represent standard grants given to Imperial. The grants are generally for a 3 year period. No new grants have been issued during the year.|**Analysis of net assets between funds**|**Unrestricted**
**Designated**
**Restricted**
**Endowment**
**Total**
Unrestricted
Designated
Restricted
Endowment|**funds**
**funds**
**funds**
**funds**
funds
funds
funds
funds|**2023**
**2023**
**2023**
**2023**
**2023**
2022
2022
2022
2022|**£**
**£**
**£**
**£**
**£**
£
£
£
£|Fund balances at 31 July|2023 are represented by:|Investments
3,889,203
-
167,825
2,210,866
6,267,894
3,529,666
613,197
113,862
2,258,394|Current assets/(liabilites)
(816,054)
618,618
-
-
(197,436)
(285,825)
-
-
-|Long term liabilites
(179,481)
-
-
-
(179,481)
-
-
-
-|2,893,668
618,618
167,825
2,210,866
5,890,977
3,243,841
613,197
113,862
2,258,394|
|**23**||||||||||||**24**|||||||||||
## **GENESIS RESEARCH TRUST**
## **NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)** _**FOR THE YEAR ENDED 31 JULY 2023**_
## **25 Related party transactions**
Investment management fees of £45,426 (2022 : £46,626) have been paid to Veritas Investment Management (UK) Limited, a company in which one of the Trustees, Mr A S Rosenfelder, has a participating interest. Mr Rosenfelder is not involved in the management of the investments as he is not registered by the FCA in the UK.
During the year, grants totalling £278,260 (2022: £nil) were made to Imperial College where Professor P R Bennett is Director of IRDB and Professor S Franks is Professor of Reproductive Endocrinology.
In addition, during the year, Professor P R Bennett and Professor S Franks received reimbursements from the Amenity Fund in relation to research costs of £8,384 and £2,876 respectively.
No trustee received remuneration in the year.
|**26**|**Cash generated from operatons**|**2023**|**2022**|
|---|---|---|---|
|||**£**|**£**|
||(Defcit)/surplus for the year|(338,317)|136,235|
||Adjustments for:|||
||Investment income recognised in statement of fnancial actvites|(141,617)|(90,585)|
||Investment management charged to portolio|45,426|46,625|
||Loss on disposal of investments|33,383|5,083|
||Fair value gains and losses on investments|42,754|(180,294)|
||Depreciaton and impairment of tangible fxed assets|-|493|
||Movements in working capital:|||
||(Increase)/decrease in debtors|(5,622)|225,698|
||Increase/(decrease) in creditors|213,962|(222,405)|
||(Decrease) in deferred income|-|(40,061)|
||**Cash absorbed by operatons**|(150,031)|(119,211)|
27 **Analysis of changes in net funds** The Trust had no debt during the year.
- 30 -
## **Issuer**
## HW Fisher
**Document generated** Tue, 9th Apr 2024 14:22:14 UTC **Document fingerprint** ed85817a1562fec1c39792d19749cca4
## **Parties involved with this document**
**Document processed Party + Fingerprint** Fri, 12th Apr 2024 16:05:33 UTC Lord Robert Winston - Signer (a4875ee99be34f60c2f440ebe723158f) Fri, 12th Apr 2024 16:17:29 UTC Andrew Rich - Signer (4704931fc201bf9a1c191878dd0e5b42)
## **Audit history log**
## **Date**
## **Action**
- Fri, 12th Apr 2024 16:17:49 UTC Andrew Rich viewed the envelope (20.254.26.207) Fri, 12th Apr 2024 16:17:29 UTC Andrew Rich viewed the envelope (89.150.28.98) Fri, 12th Apr 2024 16:17:29 UTC This envelope has been signed by all parties (89.150.28.98) Fri, 12th Apr 2024 16:17:29 UTC Andrew Rich signed the envelope (89.150.28.98) Fri, 12th Apr 2024 16:17:10 UTC Andrew Rich viewed the envelope (89.150.28.98) Fri, 12th Apr 2024 16:14:25 UTC Document emailed to arich@hwfisher.co.uk (35.178.225.23) Fri, 12th Apr 2024 16:14:25 UTC Neal Gilmore has changed the party Andrew Rich's email to arich@hwfisher.co.uk (92.1.210.156)
- Fri, 12th Apr 2024 16:14:25 UTC Sent the envelope to Andrew Rich (arich@hwfisher.co.uk) for signing (92.1.210.156)
- Fri, 12th Apr 2024 16:10:39 UTC Party email (arich@hwfisher.c.o.uk) has bounced back. The reason given is: error dialing remote address: dial tcp 198.21.5.83:0->185.151.30.166:25: connect: connection refused (167.89.116.27)
- Fri, 12th Apr 2024 16:05:34 UTC Lord Robert Winston viewed the envelope (90.208.64.22) Fri, 12th Apr 2024 16:05:33 UTC Document emailed to arich@hwfisher.c.o.uk (18.133.75.28) Fri, 12th Apr 2024 16:05:33 UTC Sent the envelope to Andrew Rich (arich@hwfisher.c.o.uk) for signing (90.208.64.22)
- Fri, 12th Apr 2024 16:05:33 UTC Lord Robert Winston signed the envelope (90.208.64.22) Fri, 12th Apr 2024 15:53:53 UTC Lord Robert Winston viewed the envelope (90.208.64.22) Fri, 12th Apr 2024 15:53:44 UTC Lord Robert Winston opened the document email. (172.226.114.0) Fri, 12th Apr 2024 7:47:29 UTC Lord Robert Winston opened the document email. (172.226.183.9)
Wed, 10th Apr 2024 23:46:31 UTC Wed, 10th Apr 2024 10:03:13 UTC Tue, 9th Apr 2024 14:30:02 UTC Tue, 9th Apr 2024 14:30:02 UTC
Wed, 10th Apr 2024 23:46:31 UTC Lord Robert Winston opened the document email. (172.224.226.0) Wed, 10th Apr 2024 10:03:13 UTC Lord Robert Winston opened the document email. (172.226.183.14) Tue, 9th Apr 2024 14:30:02 UTC Document emailed to robertwinston1540@me.com (3.10.107.35) Tue, 9th Apr 2024 14:30:02 UTC Sent the envelope to Lord Robert Winston (robertwinston1540@me.com) for signing (217.207.100.70) Tue, 9th Apr 2024 14:23:47 UTC Andrew Rich has been assigned to this envelope (217.207.100.70) Tue, 9th Apr 2024 14:23:47 UTC Lord Robert Winston has been assigned to this envelope (217.207.100.70) Tue, 9th Apr 2024 14:22:25 UTC Document generated with fingerprint bf3695d54325b6437e3c86ed7176967c (217.207.100.70) Tue, 9th Apr 2024 14:22:23 UTC Document generated with fingerprint ed85817a1562fec1c39792d19749cca4 (217.207.100.70) Tue, 9th Apr 2024 14:22:14 UTC Envelope generated by Neal Gilmore (217.207.100.70)